Gynecologic Oncology Clinical Trials
Central to the department’s mission of providing exceptional research-driven care is the development of clinical research trials, including prevention trials, innovative surgical trials and therapeutic trials. The following is a list of ongoing major therapeutic trials.
Central to the department’s mission of providing exceptional research-driven care is the development of clinical research trials, including prevention trials, innovative surgical trials and therapeutic trials. The following is a list of ongoing major therapeutic trials.
Jump to a section:
Clinical trials by disease site
Ovarian
Post-Completion of Primary Therapy
2015-0520 (bevacizumab): Phase II investigation of bevacizumab for the treatment of second-look positive epithelial ovarian cancer
Recurrent - Platinum Resistant
2016-0093 (durvalumab, tremelimumab): Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
2017-0672 (cyclophosphamide, fludarabine, LN-145, interleukin 2): Clinical study to assess efficacy and safety of LN-145 (autologous centrally manufactured tumor infiltrating lymphocytes) across multiple tumor types
2020-0420 (Avenge) This is an open-label, First-in-Human, Phase 1/2, multicenter study to evaluate the safety and efficacy of a single dose of AVB-001. AVB-001 is an encapsulated cell product engineered to produce native human interleukin-2 (hIL-2). It is delivered intraperitoneally (IP) to patients with high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.
2020-1121 (pembrolizumab, lenvatinib) Immunomodulation of the tumor microenvironment in high-grade serous ovarian cancer patients receiving pembrolizumab and lenvatinib monotherapy and combination therapy
2021-0694 (TAME) A pilot study of weekly paclitaxel, bevacizumab, and Tumor Associated Macrophage targeted therapy (zoledronic acid) in women with recurrent, platinum-resistant, Epithelial ovarian, fallopian tube or primary peritoneal cancer
Recurrent - Platinum Sensitive
2016-0677 (AZD1775, olaparib): A randomized 2-arm, non-comparative phase 2 study of AZD1775 alone or AZD1775 and olaparib in ovarian cancer patients who have progressed during PARP inhibition
Rare Tumors (Ovarian)
GOG 3051 (BOUQUET) This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors.
Low-Grade serous, primary
2019-1245 (NRG-GY019) Randomized phase III, two-arm trial of paclitaxel/carboplatin/maintenance letrozole versus letrozole monotherapy in patients with stage II-IV, primary low-grade serous carcinoma of the ovary or peritoneum
Low-grade serous, recurrent
GOG3026 A Phase II Trial of Ribociclib (LEE011) plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum
Clear-cell, recurrent
2021-0511 (EON) EON: A Single-arm Phase II study of Etigilimab (OMP-313M32) in Combination with Checkpoint Inhibition (Nivolumab) in Patients with Platinum-resistant, Recurrent Epithelial Ovarian Cancer
Recurrent Mucinous
2021-0660 (HIPEC) Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
Endometrial (Uterine)
Primary Therapy (Newly Diagnosed, Untreated)
2014-0944 Phase II study of the levonorgestrel intrauterine device alone or in combination with the mTOR inhibitor, everolimus, for the treatment of complex atypical hyperplasia and stage Ia Grade 1 endometrial cancer
Advanced or Recurrent
2017-0404 (niraparib, copanlisib): A phase Ib study of the oral PARP inhibitor niraparib with the intravenous PI3K inhibitor copanlisib for recurrent endometrial and recurrent ovarian, primary peritoneal, or fallopian tube cancer
2015-0961 (ribociclib, everolimus, letrozole): A phase II, single-arm study of ribociclib (LEE011), everolimus, and letrozole, in patients with advanced or recurrent endometrial carcinoma
Cervical, Vaginal, Vulvar
Newly Diagnosed
RTOG0724 (chemo + pelvic radiation): Phase III randomized study of concurrent chemotherapy and pelvic radiation therapy with or without adjuvant chemotherapy in high-risk patients with early-stage cervical carcinoma following radical hysterectomy
2020-0545 (CoNteSSa): FIGO 2018 stage IB2 (=2cm - <4 cm) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and ConservativeSurgery in Cervical Cancer to Preserve Fertility (NeoCon-F)
2019-0919 (Yoga) Yoga Therapy During Chemotherapy and Radiation Treatment for Local-regional Cervical Cancer
Recurrent, Metastatic
2017-0505 A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic or persistent cervical carcinoma
2022-0107 (Traction) This is a study to learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.
Rare Tumors (Cervical)
2021- 0585 (cadonilimab) Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
Multiple Solid Tumor Sites
2018-0538 (Immatics) Phase 1 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with atezolizumab in patients with recurrent and/or refractory solid tumors (ACTengine® IM)
2021-0589 (Xencor) This study is to test the safety and effectiveness of XmAb20717 for participants with advanced rare cancers.
2020-1042 (Alaunos TCR trial) A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors.
2020-0800 (Bio-Path) A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients with Advanced or Recurrent Solid Tumors
Advanced or Recurrent (Previously Treated)
2011-0216 (siRNA-EphA2-DOPC): EphA2 gene targeting using neutral liposomal small interfering RNA delivery (IND# 72924): A phase I clinical trial
Surgical Trials
2020-0165 Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
request an appointment online.